聚乙二醇化重组人粒细胞刺激因子治疗骨肉瘤化疗后白细胞减少的疗效观察  

Clinical observation of recombinant human granulocyte colony-stimulating factor in the treatment of leukocyte reduction after chemotherapy of osteosarcoma

作　　者：吴林波[1] 艾克拜尔.尤努斯 陈江涛[1] 麦麦提艾力.阿不力克木 姜大为[1] 龙志成[1] 宋兴华[1] Wu Linbo;Aikebaier·Younusi;Chen Jiangtao;Maimaitiaili·Abulikemu;Jiang Dawei;Long Zhicheng;Song Xinghua(Department of Orthopedics,the First Hospital Affiliated to Xinjiang Medical University 830054)

机构地区：[1]新疆医科大学第一附属医院骨科中心,830054

出　　处：《中国社区医师》2017年第11期82-82,84,共2页Chinese Community Doctors

摘　　要：目的:探讨聚乙二醇化重组人粒细胞刺激因子在骨肉瘤新辅助化疗后预防白细胞减少的有效性。方法:A组使用重组人粒细胞集落刺激因子,B组使用PEG-rh G-CSF治疗,对比给药间期的差异。结果:B组白细胞恢复正常天数明显小于A组,差异具有统计学意义(P<0.05)。结论:聚乙二醇化重组人粒细胞刺激因子在骨肉瘤新辅助化疗后,使白细胞恢复正常的时间较重组人粒细胞集落刺激因子短。Objective:To investigate the efficacy of pegylated recombinant human granulocyte colony-stimulating factor in the prevention of leukocyte after neoadjuvant chemotherapy for osteosarcoma.Methods:Recombinant human granulocyte colony stimulating facto was used in the A group,and PEG-rhG-CSF was used in the B group.Results:The days of white blood cells back to normal in the B group was significantly less than that in the A group,and the difference was statistically significant (P<0.05).Conclusion:Pegylated recombinant human granulocyte colony-stimulating factor in the treatment of osteosarcoma after neoadjuvant chemotherapy can shorten the recovery time of leukocyte when compared with recombinant human granulocyte colony stimulating factor.

关 键 词：聚乙二醇化重组人粒细胞刺激因子 骨肉瘤 新辅助化疗 白细胞 

分 类 号：R738.1[医药卫生—肿瘤]